In light of expanding legalization of cannabis and swelling debate about the potential risks, particularly for younger users, understanding acute cannabis effects among adolescents and emerging adults is more important than ever. Contemporary models of addiction development identify subjective drug responses as central to the developmental unfolding of drug use disorders. Despite this, surprisingly little is known about cannabis's acute subjective effects in human youths. This research utilized ecological momentary assessment (EMA) in the natural environment to identify the typical situational context of cannabis use among 85 frequent cannabis users, ages 15-24 years (M ϭ 19.8, SD ϭ 2.0; 48.2% female). Study aims were to (a) characterize momentary changes in several subjective states (i.e., stimulation, sedation, tension, craving, and high) when not using, just before cannabis use, and after use, and (b) evaluate whether cannabis responses varied with cannabis use disorder (CUD) severity or across the transition from adolescence to emerging adulthood in a correlational manner. Use of cannabis produced measurable reductions in craving and tension, as well as increases in stimulation, sedation, and "high." Participants with more CUD symptoms reported greater relief of craving and increased stimulatory response and high following use. In contrast, emerging adults reported diminished stimulatory response and high following use, relative to adolescents. Results highlight the utility of EMA for characterizing cannabis response as this behavior unfolds in daily life, during a key developmental timeframe in the pathogenesis of cannabis-use pathology.
. In particular, cannabis use in the human laboratory has enhanced self-reported alertness and stimulation, high, and sedation among adults in a dose-response manner, and these effects were similar for both smoked and oral administration (Chait & Zacny, 1992; Haney, 2009; Haney, Ward, Comer, Foltin, & Fischman, 1999; Hart, van Gorp, Haney, Foltin, & Fischman, 2001; Hart et al., 2002) .
Comparatively little research has investigated the subjective effects of cannabis in adolescents and emerging adults, and examination of how these effects relate to the severity of addiction has also been limited. Neurodevelopmental changes extending from adolescence through emerging adulthood have been linked to heightened substance-misuse vulnerability among youths (Lubman, Cheetham, & Yücel, 2015; Meier et al., 2012; Volkow et al., 2016) , and compelling evidence from animal research has suggested this liability stems, in part, from youths' unique sensitivities to the acute effects of substances. Evidence from cannabis administration studies in animals has suggested that adolescents are differentially sensitive to the acute effects of cannabis (Cha, White, Kuhn, Wilson, & Swartzwelder, 2006; Quinn et al., 2008) , and one recent human laboratory study has also suggested cannabis-response differences in male adolescents (Mokrysz, Freeman, Korkki, Griffiths, & Curran, 2016) . In addition, adolescence is marked by heightened sensitivity to general reward, that is, not drug specific, and reduced sensitivity to punishment (Doremus-Fitzwater, Varlinskaya, & Spear, 2010; . Taken together, there has been sufficient evidence that adolescents may be differentially sensitive to the acute effects of cannabis, and, thus, advancing the understanding of the unfolding of addiction requires examining subjective effects during this developmentally important period.
Adolescent subjective response, moreover, is key to contemporary etiological models of addiction. Sensitization and allostatic models, for instance, conceptualize acute subjective effects of substances as clinically relevant endophenotypes-that is, reliably measured dynamic neurobiological processes underlying addiction liability. A common premise across these models has been that repeated drug use produces neurobiological changes in the brain that heighten the individual's sensitivity to acute substance-use rewards (Koob & LeMoal, 2001; Robinson & Berridge, 1993 . This potentiation in the drug's reinforcing effects, in turn, promotes rapid emergence and strengthening of motivation for drug rewards (i.e., craving) in nonuse moments (Berridge, 2007; Robinson & Berridge, 1993 . From this perspective, differences in drug response are expected as addiction develops, such that rewarding drug responses and craving in nonuse moments should be heightened among youths with more severe addiction pathology. But, despite strong support from animal research, investigations of these core tenets of neuroadaptive models of addiction in humans have been scant, and only a few studies have examined cannabis response, more generally, among adolescents or emerging adults. Advancing understanding of the etiology of cannabis use disorder (CUD) requires leveraging newly developed technologies and ecological methods to test current theories of addiction during a pivotal period for addiction risk.
The lack of empirical testing of subjective responses to cannabis among adolescents and emerging adults has been a key research gap that stems, in part, from prohibitions on real-time examination of these effects in the human laboratory with youths in the United States. A primary focus of the current investigation was to characterize subjective responses to cannabis among adolescents and emerging adults in natural settings. This was achieved by utilizing ecological momentary assessment (EMA), a real-time in vivo approach that is well suited to capturing discrete, episodic events that are frequent and variable across situations and context (Shiffman, 2009 ). EMA has been applied to study subjective responses to several drugs of abuse among adults (Buckner, Zvolensky, & Ecker, 2013; Piasecki et al., 2011; Piasecki, McCarthy, Fiore, & Baker, 2008; Ray et al., 2010; Serre et al., 2012; Treloar, Piasecki, McCarthy, & Baker, 2014) and to a lesser extent among youths (Gwaltney, Bartolomei, Colby, & Kahler, 2008; Miranda et al., 2014) . In adult cannabis users, Buckner and colleagues (2015) showed in vivo decreases in withdrawal, craving, and negative affect at an assessment point following cannabis use. Only one other research group, to our knowledge, has studied cannabis response among younger users, ages 15-24, in vivo. Shrier and colleagues found a trend toward greater ratings of "highest high" following cannabis use for younger participants (Shrier, Walls, Rhoads, & Blood, 2013 , p. 1450 .
In the present research, we used EMA to capture subjective states previously shown to be affected by cannabis among adolescent animals and human adults (i.e., craving, stimulation, sedation, "high," and tension). Momentary data, including contextual information (e.g., location, presence of peers), was collected at (a) randomly selected times within 3-hr time blocks throughout the day, (b) immediately prior to ad lib cannabis-use episodes, and (c) just after ad lib cannabisuse episodes. Our primary objectives were twofold. First, we sought to characterize the subjective effects of ad lib cannabis use among adolescents and emerging adults. Drawing from cannabis administration studies with adults, we anticipated that stimulation, sedation, and high would be greater following cannabis use, relative to other times, whereas craving and tension would be reduced by cannabis use. Second, we sought to conduct the first human test of two key tenets of etiological theories of addiction, namely that adolescents and emerging adults with more severe CUD pathology would show heightened sensitivity to the rewarding subjective effects of cannabis use and higher levels of craving. Specifically, we examined whether subjective responses and craving varied across severity of CUD pathology in a correlational manner by using a symptom count of currently endorsed CUD criteria. We hypothesized that positive subjective effects of cannabis (i.e., increases in stimulation and high) would be enhanced for participants with more CUD symptoms. We also hypothesized that participants with more CUD symptoms would experience higher levels of craving during nonuse moments and show greater relief (reduction) of craving following cannabis use than would those with less progressed symptomatology. In addition, we anticipated a positive association between age and CUD severity that might confound results. Thus, we explored whether our hypothesized associations were specific to CUD severity or applied, more generally, to age-related differences associated with the transition from adolescence to emerging adulthood.
Method Participants
Participants (n ϭ 85) were recruited from the community to participate in a study of whether a medication affects cannabis use.
Recruitment efforts included posting advertisements in settings
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frequented by youths, such as recreational settings, public buses, and high schools, as well as advertising on social media. Study staff also set up informational tables at schools, sporting events, festivals, and public beaches. Eligible participants were 15-24 years of age who used cannabis at least twice weekly in the past 30 days. This criterion was used to increase the likelihood of capturing marijuana use in the natural environment during the study. Those seeking formal cannabis treatment in the past 30 days were excluded. Additional exclusion criteria included current Axis I psychopathology (other than cannabis, alcohol, nicotine, or disruptive behavior disorders), active suicidality or psychotic symptoms, and medical conditions or medications that contraindicated taking study medication. Female adolescents were ineligible if they were pregnant, nursing, or unwilling to use birth control.
Procedure
This study was part of a larger clinical trial registered at http:// clinicaltrials.gov (NCT01110434) and described in Miranda and colleagues (2017) . Participants who met provisional eligibility criteria based on a brief telephone screening completed a comprehensive, in-person interview to confirm eligibility. Written informed consent was obtained from 18-to 24-year-old participants; assent was obtained from minors, and their parents provided written informed consent. The Brown University Institutional Review Board approved the study protocol (0903992676).
Data for the present study were from a prerandomization, premedication EMA period of approximately one week. Participants were not instructed to reduce or otherwise alter substance-use patterns. Participants completed assessments in their usual settings via handheld wireless devices (Omnia; Samsung Electronics, Ridgefield Park, NJ) with software developed for this study. Instructions were in simple English, and participants recorded data by tapping directly on the screen. Participants recorded responses at several times each day, and a combination of randomly prompted and user-initiated reports ensured adequate coverage of focal variables. Participants were compensated $10 per day for complying with the EMA protocol.
Baseline Assessments
Demographic information, including participant sex (0 ϭ male; 1 ϭ female), age, and racialϪethnic background, was collected at a baseline session.
Cannabis-use disorder. The severity of CUD was quantified by symptom count based on participant responses to the Kiddie Schedule for Affective Disorders for School-Age Children (Kaufman et al., 1997), a clinician-administered interview based on criteria according to the Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR; American Psychiatric Association, 2000). Although abuse and dependence diagnoses were determined through case consensus, a symptom count was used to more closely match the DSM-5 diagnostic system (American Psychiatric Association, 2013), which excludes legal problems and assesses CUD on a continuum with mild (2-3 symptoms) moderate (4 -5 symptoms), and severe (6ϩ symptoms) specifiers. Participants could meet up to 10 DSM-IV-TR criteria, and all criteria were represented in this sample.
Cannabis use. A 90-day timeline follow-back (TLFB) interview (Sobell & Sobell, 1992 ) assessed cannabis use prior to the EMA period. To facilitate accurate reporting of the quantity of cannabis use on a specific day, participants estimated how much cannabis they used by weighing a surrogate substance (i.e., oregano). When participants shared cannabis with others, the total weight was divided by the number of users. This method of estimating daily quantities of cannabis use has shown evidence of reliability and validity (Mariani, Brooks, Haney, & Levin, 2011; Norberg, Mackenzie, & Copeland, 2012) , and the TLFB has been shown to correlate strongly with plasma THC levels (Hjorthøj, Fohlmann, Larsen, Arendt, & Nordentoft, 2012) .
Momentary Assessments
Participants received random prompts each day, delivered by the device within 3-hr time blocks. Device-delivered random prompts "timed out" after 2 min; however, participants had the option to the delay the completion of random prompt assessments for up to 20 min. Prompts that were not completed in that time frame were marked as missed. Other features, such as an alarm set by participants to avoid assessments while sleeping, made it user-friendly.
Cannabis use. Participants were instructed to initiate a "beginpot report" just before starting to use cannabis and an "end-pot report" as soon as they finished smoking. Participants were trained to complete cannabis reports for every joint, blunt, bong, bowl, or any other way cannabis was used during the study. Participants estimated how many grams of cannabis they used and reported how many people they shared cannabis with.
Other substance use. Recent nicotine use was assessed for all record types with the single question "When did you last smoke a cigarette?" Response options reflected current smoking, last 15 min, last hour, last 2 hr, more than 2 hr ago, or no cigarette smoking yet that day. Participants self-initiated alcohol reports with a procedure parallel to that for cannabis-use reports, before and after each alcoholic beverage consumed.
Subjective states. Visual analog bars (converted to discrete, 11-point scales) assessed a number of acute cannabis effects and mood states. Prompts stated, "How __ do you feel right now?" with end-point anchors not at all and extremely. Subjective responses included energized, excited, sedated, sluggish, and high. Energized and excited were assessed for all record types, whereas acute effects of cannabis (i.e., sedated, sluggish, and high) were assessed for only cannabis reports. Items were averaged to form stimulation (energized, excited: ␣ ϭ .81 nonuse, ␣ ϭ .73 begincannabis, ␣ ϭ .74 end-cannabis), tension (tense, stressed: ␣ ϭ .82 nonuse, ␣ ϭ .54 begin-cannabis, ␣ ϭ .59 end-cannabis), and sedation (sedated, sluggish: ␣ ϭ .53 begin-cannabis, ␣ ϭ .66 end-cannabis) composites. Strong correlations between these items (rs ϭ .66, .58, and .48, for stimulation, tension, and sedation, respectively; ps Ͻ .001) further supported their combination.
Craving-urge. Visual analog bars (converted to discrete, 11-point scales) assessed urge to use cannabis. Prompts stated "How strong is your urge to use pot right now?" with end-point anchors no urge and strongest ever.
Contextual variables. Participants indicated their present company using multiple checkboxes. Categories of friends and boyϪgirlfriend were combined to form a presence of peers variable (0 ϭ peers not present; 1 ϭ peer present). Current location was assessed with forced choices (choose only one). This document is copyrighted by the American Psychological Association or one of its allied publishers.
Time of day and social day. All reports were dateϪtime stamped and coded into four 6-hr blocks (e.g., 6 a.m. to noon) as a time-of-day covariate. Nesting of reports within days was identified according to participants' individual social schedules (e.g., 8 a.m. to 4 a.m.) rather than calendar days.
Analytic Approach
Two-level, random-intercept models with momentary reports (Level 1) nested within participants (Level 2) were estimated in SAS 9.3 PROC GLIMMIX (categorical outcomes) and PROC MIXED (continuous outcomes), with restricted maximum likelihood estimation. This approach is robust to unique timing of reports and variable numbers of reports for each participant in the study (Gibbons, Hedeker, & DuToit, 2010; Raudenbush & Bryk, 2002; Singer & Willett, 2003) . The inclusion of a level indicating social day in additional model tests did not alter the pattern of fixed effects, and, thus, this level was not included.
An initial model predicted the log odds of engagement in cannabis use from several time-varying contextual variables; person-level aggregates of contextual variables; and time-invariant, person-level covariates. Next, a series of models addressed the first study aim: characterizing the effects of cannabis on subjective responses (i.e., stimulation, tension, sedation, high, and craving) in the natural environment. A categorical variable indicated report type to examine the differences in subjective states for nonuse random prompts, begincannabis reports, and end-cannabis reports. The reference contrasts compared begin-and end-cannabis reports to nonuse reports, as well as end-cannabis reports to begin-cannabis reports.
Next, main and interactive effects of the CUD-symptom-count variable with report type were added to test whether differences in subjective effects varied as a function of CUD severity. Main effects represented the effect of disorder severity on subjective responses, in general, for the reference category. Interactive effects with report type evaluated the influence of disorder severity on differences in subjective responses across report types. All contextual and person-level variables from initial analyses were included in final models to evaluate whether these covariates accounted for the pattern of results, with continuous covariates person-and grand-mean-centered, respectively. Last, main and interactive effects of age with report type were added to test whether the same pattern of differences in subjective effects would be found for CUD and age.
Results

Participant Characteristics
Eighty-five participants (48.2% female; M age ϭ 19.75 years, SD ϭ 2.0, range ϭ 15-24) provided EMA data. The majority self-identified as White or Caucasian (48.2%) or Black or African American (29.4%); 17.6% indicated Hispanic or Latino ethnicity. At baseline, participants reported using marijuana on 69.91% of the past 90 days (SD ϭ 27.04) and used an average of .65 g of marijuana (SD ϭ .53) per use day (see Table 1 for a summary of participant characteristics across varying severity of CUD symptom counts). CUD groups were created for descriptive purposes, but all other analyses used the original CUD symptom count, ranging from 0 to 9 in this sample, with the average participate reporting moderate severity CUD (M ϭ 4.4, SD ϭ 2.1).
EMA Compliance
Participants completed from 11 to 73 combined random prompt, begin-cannabis, and end-cannabis reports during the study (M ϭ 33.9, SD ϭ 14.1) and from 1 to 16 of these reports per day (M ϭ 6.0, SD ϭ 2.6). Devices delivered 2,065 random prompts, of which 1,730 were completed (83.8%). The average number of devicedelivered prompts per day was 3.7 (SD ϭ 1.6). The majority of participants (89.3%) missed 10 or fewer random prompts. The average number of missed random prompts across all study days, per participant, was 5.2 (SD ϭ 3.6). The number of missed random prompts was correlated with the baseline percentage of cannabisuse days (r ϭ .22, p Ͻ .001) but was not correlated with CUD symptom count, age, or grams of cannabis smoked per use day (ps ϭ .802, .872, and .119, respectively). Male participants also had more missed random prompts than did female (M difference ϭ Descriptive Information for Reports in the Natural Environment Figure 1 illustrates the flow of EMA data management. Random prompts delivered after substance use were removed to avoid confounding with acute responses (n ϭ 462). Cannabis reports occurring after alcohol use, which occurred infrequently (n ϭ 9), were also removed to disentangle cannabis and alcohol effects; reports involving concurrent cannabis and alcohol use were retained (see later). Although multiple end-cannabis reports were permissible, only the first begin-cannabis report within the participant's social day was included, to exclude carryover effects from previous use (n ϭ 212 excluded second begin-cannabis reports). A substantial proportion of begin-cannabis reports were completed after smoking had already been initiated (n ϭ 167). Over half of these were within 5 min of initiating smoking (n ϭ 99; range ϭ 1-122 min). THC is detectable in plasma seconds after first inhalation "puff" of a cannabis cigarette, however, and peak levels are observed between 3 min and 10 min (Grotenhermen, 2003) ; therefore, these analyses followed the most stringent approach of removing any begin-cannabis reports recorded after initiation of use. End-cannabis reports occurring Ͼ3 hr (180 min) after finishing smoking were also excluded (n ϭ 6); this cutoff was based on literature showing declining THC concentrations between 2 hr and 3 hr after inhalation of cannabis, with the THC concentration diminished by 3 hr (Grotenhermen, 2003) . This resulted in 1,268 nonuse, random-prompt reports; 153 begin-cannabis reports; and 508 end-cannabis reports (see Figure 1) .
Characterizing Cannabis Use
Participants used, on average, .73 g of cannabis on days they smoked in the natural environment (SD ϭ .63, Mdn ϭ .56). The average time of initiating cannabis use was 4:18 p.m. The primary methods of administration were via a blunt (52.6%) or bowl (28.1%), with less common use via bong (8.9%), joint (7.3%), or other (3.2%). Although uncommon, participants indicated concurrent alcohol use for 17 end-cannabis reports (3.4%) that had been retained in analyses because no alcohol use was reported earlier that day or at a begin-cannabis report. Concurrent use of nicotine cigarettes was more common (n ϭ 73; 14.5% of end-cannabis reports). Exclusion of alcohol and nicotine co-use reports did not alter the pattern of results that follows. Table 2 presents odds ratios from mixed-effects models evaluating the situational context of cannabis use (i.e., comparing non- This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. 
Craving and Subjective Responses
Within-and between-subjects variability. A primary aim of this work was to capture the subjective effects of cannabis use in the usual settings of adolescents and emerging adults. An important step toward that goal was to evaluate whether there was variability in subjective states across EMA moments and persons. Note. OR ϭ odds ratio; CI ϭ confidence interval; LL ϭ lower limit; UL ϭ upper limit. a Twenty-one location reports (1.2%) were missing. Thus, 491 end-cannabis reports were compared to 1,264 reports from nonuse times. Missing data, albeit minimal, occurred when the device malfunctioned and prematurely exited a report. b Time-invariant, person-level continuous variables were centered at the grand mean.
c Based on reports from the baseline 90-day timeline follow-back.
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states, about one third of the variability in craving, stimulation, and tension was attributable to person-level influences. Table 3 presents unstandardized parameter estimates from mixed-effects models, and standardized effects are reported in text. The middle panel of Table 3 presents comparisons of subjective effects across nonuse random prompts, begin-cannabis reports completed just before use, and end-cannabis reports completed after participants finished using cannabis. Tabled results accounted for the influence of momentary total grams of cannabis smoked (i.e., the momentary report of grams smoked, centered at each participant's own average), person-average grams (i.e., the participant's average grams per smoking event across the study, centered at the overall average for all participants), and time spent smoking (i.e., the participant-reported time since smoking, with nonuse and begin-cannabis reports coded as 0). The same pattern of results was found when other covariates from Table 2 were included (see Table 3 in the online supplemental materials).
Craving. Craving was elevated just before cannabis use (␤ ϭ .71, 95% confidence interval (CI) [.57, .84 Associations Between CUD Symptoms, Craving, and Subjective Responses Table 3 (middle panel) presents models including main and interactive effects of CUD symptom count on subjective states. Main effects represent the effect of CUD symptoms on the intercept of subjective states (i.e., the reference category), and interactive effects represent the relation of CUD symptoms to subjective states across report types. Consistent with our hypotheses, CUD symptom count was related to greater craving at nonuse times (b ϭ .32, ␤ ϭ .15, 95% CI [.02, .28], p ϭ .029) and marginally related to reduced stimulation at nonuse times (b ϭ Ϫ.16, ␤ ϭ Ϫ.12, 95% CI [Ϫ.25, -.01], p ϭ .075). As predicted, CUD symptoms also affected the difference in craving and stimulation after smoking, relative to nonuse times. Each additional CUD symptom was associated with an additional one quarter to one third of a point reduction in craving following use (b ϭ Ϫ.28, ␤ ϭ Ϫ.16, 95% CI [Ϫ.25, Ϫ.07], p Ͻ .001), and CUD symptoms also enhanced differences in stimulation after use (b ϭ .13, ␤ ϭ .10, 95% CI [.01, .19 ], p ϭ .035). CUD symptoms did not alter the pattern of subjective tension, sedation, or high. Figure 2 illustrates modelbased (empirical Bayes) estimates of subjective craving, stimulation, and high when not using, just before use, and after use as a function of CUD symptom count. Models were replicated including only the first, paired begin-and end-cannabis reports of each social day (see Table 4 in the online supplemental materials). Additionally, a summary of differential associations of individual CUD symptoms with subjective states is provided in Table 5 in the online supplemental materials.
Associations Between Age and Subjective Response
The pattern of findings for age differed from that for CUD (see Table 3 ). Where CUD symptoms were associated with blunted stimulation when not using and enhanced stimulatory effects of use, age was associated with greater stimulation when not using (b ϭ .19, ␤ ϭ .14, 95% CI [.02, .27 ], p ϭ .026) and blunted stimulatory effects of use (b ϭ Ϫ.18, ␤ ϭ Ϫ.13, 95% CI [Ϫ.23, This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
.04], p ϭ .004). Age was also associated with blunted high following cannabis use (b ϭ Ϫ.22, ␤ ϭ Ϫ.12, 95% CI [Ϫ.22, Ϫ.02], p ϭ .021) where CUD symptoms were marginally associated with enhanced high. Age was also not associated with craving for any report type, whereas these were some of the strongest effects of CUD symptoms.
Discussion
Findings supported our predictions regarding the effects of ad lib cannabis use on subjective responses in adolescents and emerging adults in real-world settings. Cannabis use produced acute, measurable increases in stimulation, sedation, and high, as well as reductions in craving and tension. In addition, as predicted, participants with more CUD symptomatology reported sharper increases in stimulation and decreases in craving following use relative to those with fewer CUD symptoms. Together, these findings provide additional support for the clinical relevance of subjective responses to cannabis as factors that either underlie or coincide with the development of CUD.
Our work features EMA as a method for characterizing aspects of cannabis use among adolescents and emerging adults in real time in their natural environments during an important developmental period in the pathogenesis of CUD. The fact that craving was heightened prior to use and reduced by use supported craving as an important proximal predictor of use. Craving ratings then converged at low levels for end-cannabis reports, regardless of CUD, suggesting that use unilaterally reduced craving for all participants. We did not anticipate that stimulation would be heightened and tension lessened prior to use. Differences emerging prior to use may indicate that some components of subjective "responses" to cannabis occur in anticipation of smoking. Preuse changes were found regardless of whether begin-cannabis reports self-initiated after smoking had already begun were retained or excluded, and supplemental analysis of paired begin-and end-use reports replicated these findings. Nonetheless, we cannot discount that the internal monitoring of subjective states may have influenced when participants self-initiated a cannabis-use report, thus limiting the ecological validity of these assessments.
The overall finding that cannabis use paradoxically increased stimulation and sedation as well as high is consistent with adult administration studies (Haney et al., 1999; Hart et al., 2001 Hart et al., , 2002 . But, as predicted, results also showed that participants with more severe CUD experienced greater cannabis-induced stimulation. It is noteworthy that neurocircuitry governing the reinforcing effects of cannabis and other drugs (i.e., mesocorticolimbic circuits) undergo extensive neuromaturation during adolescence and emerging adulthood. These fundamental changes heighten youths' hedonic sensitivity and promote developmentally normative increases in impulsive and rewardseeking behavior. Taken together, the confluence of hypersensitivity to the positive reinforcing effects of cannabis and other drugs paired with dampened self-control and increased propensity for reward-seeking behavior appears to confer liability for hazardous drug use and the development of drug-related problems (Lubman et al., 2015; Lubman, Yücel, & Hall, 2007) . This study, which found a positive association between CUD severity and subjective rewarding effects of cannabis use, but negative association between age and stimulatory response, provides cross-sectional support for these notions.
We also found that craving was elevated just prior to cannabis use and depressed following use, relative to nonuse times, with effects strengthened among those with more CUD symptoms. Greater CUD pathology was also associated with higher levels of craving in nonuse moments. Craving is a chief motivational determinant of drug use in most contemporary models of addiction. Laboratory studies have consistently shown that cannabis cues evoke craving under controlled conditions and that individuals with dependence and heavier users show stronger craving than do lighter and less dependent users (Norberg, Kavanagh, Olivier, & Lyras, 2016) . Findings from this study are consistent with research that shows alcohol and cannabis craving is experienced by adolescents and adults, is higher on use days than nonuse days, and is reduced by use (Buckner et al., 2015; Ramirez & Miranda, 2014) .
Finally, there is compelling evidence from animal models that adolescents differ from adults in how they respond to the acute effects of substance use. Most of the work has focused on alcohol, and findings have generally shown that adolescent rodents from outbred strains not only typically drink two-three times more alcohol than do adults but are less sensitive to the aversive, sedative, and motor-impairing effects of alcohol, while showing greater sensitivity to alcohol's stimulatory and social-facilitating effects than do adults (Quoilin, Didone, Tirelli, & Quertemont, 2010; Spear, 2011) . These alcohol sensitivities often persist into adulthood after chronic alcohol exposure during adolescence (see Spear & Swartzwelder, 2014 , for review), perhaps contributing to the greater propensity for high levels of alcohol use in adulthood after adolescent alcohol exposure Windle et al., 2009) . Only one human laboratory study compared the acute effects of cannabis in male adolescents, ages 16 -17 years, and adults, ages 24 -28 (Mokrysz et al., 2016) . Compared to adults, adolescents had blunted subjective high and greater impairment of psychotomimetic and inhibitory processes but also enhanced alertness relative to young adults. Our findings use different assessments in vivo in male and female participants and thus are not directly comparable but support the notion that adolescents have enhanced stimulatory responses to cannabis relative to emerging adults. Findings for subjective high were contradictory to those for Mokrysz and colleagues (2016) , with our adolescents showing greater subjective high than did their emerging-adult counterparts.
There were several limitations to this study. First and foremost, the cross-sectional nature of this work leaves unanswered the important question of directionality in the relationship between CUD symptom course and subjective responses and craving. Because we assessed cannabis problems at only one time point, our findings cannot differentiate between preexisting vulnerability and neuroadaptations that accompany disorder progression. Additionally, feelings of sedation, sluggishness, and high were not assessed at nonuse times in this study, limiting our understanding of CUD effects on sedative and high outcomes. Multiwave longitudinal studies that employ intensive momentary research methods with more comprehensive assessments of subjective states at use and nonuse times are necessary to track adolescents' responses to cannabis and craving over time and prospectively evaluate the causal pathways posited to underlie addiction etiology. Short of these limitations, the presThis document is copyrighted by the American Psychological Association or one of its allied publishers.
ent study provides a first look at subjective cannabis responses, in general, as well as how these responses may relate to the developmental unfolding of CUD. Additional limitations include the participant selection criteria; methodological limitations; study duration; and a host of putative influences on subjective responses not directly assessed, accounted for, or tested in the present research. First, we studied adolescent and emerging-adult cannabis users who varied in terms of severity of CUD symptomatology but may not be representative of adult users who have struggled with addiction for many years. Consequently, our findings may not generalize to older cannabis users, and this limitation may be especially salient for subjective responses to cannabis. Although most addiction theories predict early years of addiction are marked by heightened sensitivity to rewarding drug effects, they differ in their predictions about how these changes evolve as individuals develop more severe addiction. Allostatic and chronic tolerance models predict that drug use produces less potent acute positive effects as people progress in the addiction-pathology continuum. By contrast, sensitization theories purport that individuals experience greater stimulant effects as they develop more severe drug problems. Future research is needed to evaluate whether these patterns persist or change as individuals develop longer and more problematic cannabisuse histories.
Next, data were culled from a prerandomization, premedication period of a longer clinical trial evaluating a pharmacotherapeutic intervention for cannabis misuse (Miranda et al., 2017) . Thus, participants were frequent cannabis users not seeking formal treatment but willing to engage in a study designed to reduce cannabis use. Inasmuch as this influenced results, findings may not generalize to other users. Additionally, participants were not drug-tested for cannabis metabolites during the period comprising data for the present analyses, and cannabis potency was not assessed. Last, the 7-to 14-day monitoring window is short. This concern is mitigated, however, by the frequency of cannabis use in this sample. Results are from 1,929 ecological reports over 542 distinct social days and 85 cannabis-using adolescents and emerging adults who reported, on average 3.4 cannabis use days during the study period. Participant characteristics were therefore favorable, allowing for examination of several cannabis use episodes across a range of CUD symptomatology.
On the whole, research has suggested that the developmental stage of adolescence is well suited to promoting cannabis misuse, potentially via developmentally linked differences in subjective responses. Yet, understanding of subjective response as a phenotypic marker of risk for developing cannabis addiction in humans is lacking, particularly from adolescence through emerging adulthood-a crucial window for development of CUD. Thus, characterizing the acute effects of cannabis in youths is imperative for determining factors that confer liability to continued cannabis use and the development of CUD. Our findings provide the first human evidence, albeit correlational, that the acute subjective responses to cannabis use are associated with CUD severity.
